Clearmind Medicine (Nasdaq: CMND) files Japanese patent for MEAI depression therapy
Rhea-AI Filing Summary
Clearmind Medicine Inc. filed a Form 6-K highlighting a press release on the publication of a Japanese patent application for proprietary compositions containing 5-Methoxy-2-aminoindan (MEAI) to treat depression. This step adds to the company’s global intellectual property portfolio around its flagship non-hallucinogenic molecule.
Clearmind describes a large and growing market for anxiety and depression treatments and broader behavioral health. It notes about 3 million diagnosed cases of Major Depressive Disorder in Japan and outlines an MEAI-based pipeline that includes depression, alcohol use disorder, metabolic conditions such as weight loss, and other mental disorders. The company reports an intellectual property estate of nineteen patent families with 31 granted patents worldwide.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
neuroplastogen-derived therapeutics medical
5-Methoxy-2-aminoindan (MEAI) medical
Major Depressive Disorder (MDD) medical
selective serotonin reuptake inhibitors (SSRIs) medical
forward-looking statements regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Clearmind Medicine (CMND) announce in its May 2026 Form 6-K?
What is MEAI in Clearmind Medicine’s (CMND) depression pipeline?
How extensive is Clearmind Medicine’s (CMND) intellectual property portfolio?
What mental health markets does Clearmind Medicine (CMND) highlight?
What is the scale of depression in Japan mentioned by Clearmind Medicine (CMND)?
Beyond depression, what conditions is Clearmind Medicine (CMND) researching with MEAI?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: May 2026
Commission file number: 001-41557
CLEARMIND MEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Attached hereto and incorporated herein is the Registrant’s press release issued on May 29, 2026, titled “Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment”.
The first six paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
EXHIBIT INDEX
| Exhibit No. | ||
| 99.1 | Press release titled: “Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Clearmind Medicine, Inc. | ||
| (Registrant) | ||
| Date: May 29, 2026 | By: | /s/ Adi Zuloff-Shani |
| Name: | Adi Zuloff-Shani | |
| Title: | Chief Executive Officer | |
3
Exhibit 99.1
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a Japanese Patent Application for its proprietary compositions comprising 5-Methoxy-2-aminoindan (MEAI) for the treatment of depression.
This advancement strengthens Clearmind’s robust intellectual property portfolio, which already includes multiple granted patents and applications worldwide. MEAI, the company’s flagship non-hallucinogenic molecule, is designed to offer a safer, more accessible alternative to traditional antidepressants and emerging psychedelic-based therapies.
Depression remains one of the leading causes of disability worldwide. Current treatments, primarily selective serotonin reuptake inhibitors (SSRIs) and other conventional antidepressants, often come with limitations including delayed onset of action, side effects, and high rates of treatment resistance.
The global market for anxiety and depression treatments is experiencing steady growth. Estimates place the market size at approximately $16- 22.65 billion in 2025, with projections reaching $19–30 billion by 2030- 2031, driven by rising mental health awareness, increasing prevalence of disorders, and demand for innovative therapies. The broader behavioral and mental health market is significantly larger, valued at around $185 billion in 2025 and expected to approach $350 billion by 2035.
In Japan, mental health challenges are pronounced due to societal factors such as work-related stress. The country has approximately 3 million diagnosed cases of Major Depressive Disorder (MDD).
Clearmind continues to expand its MEAI-based pipeline, with ongoing research into alcohol use disorder, metabolic disorders such as weight loss, and various other mental disorders. The company’s IP portfolio now spans multiple jurisdictions, reinforcing its position in the rapidly evolving neuroplastogen and mental health therapeutics space.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of the global market for anxiety and depression treatments and the behavioral and mental health market and how the Company continues to expand its MEAI-based pipeline, with ongoing research into alcohol use disorder, metabolic conditions, and other mental disorders. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.